Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Bioxyne gets ready to raise

Bioxyne (ASX:BXN) has been granted a trading halt by the ASX, pending details of a capital raising.

Bioxyne gets ready to market its probiotics in China via

Bioxyne’s (ASX:BXN) shares were last trading 10.5% higher intra-day after signing an agreement to market its probiotic products in China using the e-commerce platform starting in Q2, 2017.

Bioxyne Ltd starts clinical trial for gut disease

Bioxyne Ltd (ASX:BXN) is the merged entity of Hunter Immunology and Probiomics. The company’s lead asset is a novel drug designed to treat chronic obstructive pulmonary disease.

Board Exercises Options


Appendix 4C - March quarterly


Bioxyne Announces 2016 Goals


Bioxyne Investor Presentation